Skip to main content
Premium Trial:

Request an Annual Quote

Jury Says Stratagene Must Pay Invitrogen $7.8M for Infringing IP

This update clarifies that a jury, not the court, said Stratagene should pay the damages. The presiding judge must still weigh in.
 
NEW YORK (GenomeWeb News) — A jury said Stratagene should pay Invitrogen nearly $8 million in damages for infringing its patents, or around four times less than Invitrogen had hoped to win, Stratagene said today.
 
Specifically, the jury determined that Invitrogen's 4,981,797 patent involving a process for developing competent cell productsis is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products.
 
The judge presiding over the case has yet to make a final judgment, and Stratagene may still appeal the verdict.
 
The jury awarded Invitrogen a 15-percent royalty rate on sales between 1997 and 2004 for a total of $7.8 million in damages, Stratagene said.
 
The jury also found Stratagene “willfully infringed the patent between the years 1997 and 2001” but determined that “Invitrogen was not entitled to lost profits because Stratagene has had a non-infringing manufacturing process for competent cells," Stratagene said.
 
The decision comes 10 months after the US Court of Appeals for the Federal Circuit overturned an earlier ruling by the US District Court for the District of Western Texas, which had ruled that Stratagene’s products did not infringe on Invitrogen’s IP. The case was then sent back to US District Court.
 
Invitrogen had sought $32 million in damages based on a lost profits argument, Stratagene said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.